Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hepatology

Understanding CBAS1: A Guide for Parents and Guardians

At a Glance

CBAS1 is a rare inherited liver condition caused by HSD3B7 deficiency. Early bile acid replacement, often with cholic acid, can improve fat and vitamin absorption and help limit abnormal bile acid buildup, while monitoring tracks liver health, growth, and vitamins.

Receiving a diagnosis of CBAS1, also known as HSD3B7 deficiency, for your child can feel like the ground has shifted beneath you. It is natural to feel a sense of shock, fear, or even panic when you hear the words “rare liver disease” [1]. However, it is important to know that CBAS1 is a specific type of liver condition that has an evidence-based treatment addressing the underlying biological cause [2][3].

What is CBAS1?

CBAS1 stands for Congenital Bile Acid Synthesis defect type 1. It is an inherited condition where the liver lacks a specific enzyme (a protein that helps the body perform chemical reactions) called HSD3B7 [4]. Because of this missing enzyme, your child’s liver cannot complete the process of making normal primary bile acids, which are essential for digestion and overall liver health [5].

This condition is extremely rare. A European survey estimated a minimum prevalence of about 0.99 cases per 10 million, though experts note it is likely underdiagnosed, and early reports documented around 100 cases worldwide [6][7]. While the rarity can make you feel isolated, it also means that your child’s care team will focus on very specialized, targeted treatments.

The Biology: Why Bile Acids Matter

To understand how CBAS1 affects your child, it helps to look at the two main roles bile acids play in the body:

  1. Removing Waste and Protecting the Liver: Normally, the liver produces bile acids to help flush out waste. Without the HSD3B7 enzyme, the process gets “stuck.” Instead of making healthy bile acids, the liver produces abnormal versions [4]. These abnormal acids build up and can damage liver cells over time, potentially leading to scarring or cirrhosis (permanent liver damage) if left untreated [8].
  2. Absorbing Nutrients: Healthy bile acids help emulsify fats and absorb fats and fat-soluble vitamins—specifically vitamins A, D, E, and K [8]. Because children with CBAS1 lack these normal bile acids, they often struggle to absorb these nutrients, which can lead to:
    • Poor weight gain or “growth faltering” [2].
    • Vitamin D deficiency, which can cause rickets (weakened bones) [2].
    • Vitamin K deficiency, which can lead to easy bleeding or bruising [9].

Managing the Emotional Impact

The journey to a diagnosis for a rare liver disease is often long and exhausting, involving many tests and specialists [10]. It is common for parents to feel guilt, self-blame, or a “panic spiral” of “what ifs” [11].

Please know that you are not alone in these feelings. Many caregivers of children with rare genetic conditions report that the first year is a period of intense adjustment as they learn to navigate a “new normal” [1]. Finding a community—whether through a formal support group or a social worker—can significantly reduce the sense of isolation and help you feel more empowered in your child’s care [12].

Why Early Diagnosis Changes Everything

The most critical thing to understand about CBAS1 is that the liver damage is often manageable with bile acid replacement therapy [3].

By providing the body with the bile acids it cannot make on its own (such as cholic acid), the treatment does two things: it helps the body absorb vitamins and fats, and it sends a signal to the liver to stop producing the abnormal acids [2]. In observational studies, many children who began treatment early showed marked improvements in liver health, with some seeing previous liver scarring regress over time [3]. While every child’s journey is unique and liver disease progression can still occur depending on existing damage, this treatment offers a clear path forward [13].

How CBAS1 is Inherited

CBAS1 is an autosomal recessive condition. This means that for a child to have the disease, they must inherit two pathogenic (disease-causing) copies of the HSD3B7 gene—one from each parent [4]. Parents are typically “carriers” who have one changed gene and one normal gene, and they usually show no symptoms themselves. When both parents are carriers, there is a 25% chance with each pregnancy that the child will have CBAS1. Knowing this can be helpful for family planning and for testing other children in the family; genetic counseling is highly recommended [14].

Common questions in this guide

What is CBAS1, also called HSD3B7 deficiency?
CBAS1 is a rare inherited liver condition caused by a missing or poorly working HSD3B7 enzyme. Without this enzyme, the liver cannot make normal bile acids needed for digestion, vitamin absorption, and liver health.
How can CBAS1 affect my child’s growth, vitamins, and liver?
Abnormal bile acids can build up and injure liver cells, potentially causing scarring or cirrhosis if the condition is untreated. Reduced absorption of fats and vitamins can contribute to poor weight gain, vitamin D deficiency and rickets, or vitamin K deficiency with easy bleeding or bruising.
What treatment is used for a child with CBAS1?
Bile acid replacement therapy, such as cholic acid, provides the bile acids the body cannot make normally. It can improve the absorption of fats and fat-soluble vitamins and signal the liver to reduce production of abnormal bile acids.
Can treatment improve liver damage caused by CBAS1?
Early bile acid treatment can lead to marked improvement in liver health, and some children have regression of earlier liver scarring. The outlook depends partly on how much damage was present before treatment, so continued specialist monitoring remains important.
How is CBAS1 inherited, and what does it mean for future pregnancies?
CBAS1 is inherited in an autosomal recessive pattern, meaning a child receives two changed HSD3B7 gene copies, one from each parent. When both parents are carriers, each pregnancy has a 25% chance of resulting in a child with CBAS1, so genetic counseling can help with family planning and testing relatives.
What should the care team monitor in a child with CBAS1?
Monitoring may include liver health, growth, and whether the child is absorbing enough fat-soluble vitamins A, D, E, and K. Parents can also ask about their child’s specific HSD3B7 changes, treatment response, long-term liver goals, and coordination among specialists.

Get notified when new evidence is published on Congenital bile acid synthesis defect type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Becoming a Rare Disease Parent: An Interpretative Phenomenological Analysis of Parent-Caregivers' Postpartum Experiences.

    Davidson HR, Gelles S, Keller KR, et al.

    Qualitative health research 2024; (34(1-2)):126-140 doi:10.1177/10497323231205419.

    PMID: 37879105
  2. 2

    Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets.

    Ahmad O, Nogueira J, Heubi JE, et al.

    Journal of the Endocrine Society 2019; (3(2)):397-402 doi:10.1210/js.2018-00314.

    PMID: 30746501
  3. 3

    Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.

    Gonzales E, Matarazzo L, Franchi-Abella S, et al.

    Orphanet journal of rare diseases 2018; (13(1)):190 doi:10.1186/s13023-018-0920-5.

    PMID: 30373615
  4. 4

    Substrate specificity and kinetic mechanism of 3β-hydroxy-Δ5-C27-steroid oxidoreductase.

    Gardner SM, Vogt A, Penning TM, Marmorstein R

    The Journal of biological chemistry 2024; (300(12)):107945 doi:10.1016/j.jbc.2024.107945.

    PMID: 39505210
  5. 5

    Tandem mass spectrometric determination of atypical 3β-hydroxy-Δ5-bile acids in patients with 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency: application to diagnosis and monitoring of bile acid therapeutic response.

    Zhang W, Jha P, Wolfe B, et al.

    Clinical chemistry 2015; (61(7)):955-63 doi:10.1373/clinchem.2015.238238.

    PMID: 25931455
  6. 6

    Attempt to Determine the Prevalence of Two Inborn Errors of Primary Bile Acid Synthesis: Results of a European Survey.

    Jahnel J, Zöhrer E, Fischler B, et al.

    Journal of pediatric gastroenterology and nutrition 2017; (64(6)):864-868 doi:10.1097/MPG.0000000000001546.

    PMID: 28267072
  7. 7

    The Diagnostic Saga of a Rare Congenital Bile Acid Synthesis Disorder: A Case Report.

    Yazbeck N, Hanna-Wakim R, Noun D, Karam PE

    Clinical medicine insights. Pediatrics 2025; (19()):11795565251340558 doi:10.1177/11795565251340558.

    PMID: 40809789
  8. 8

    [Infant with 3β-hydroxy-Δ(5)-C27 steroid dehydrogenase deficiency: report of two cases and literatures review].

    Li X, Huang Z, Wang H

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2015; (53(5)):360-5.

    PMID: 26080666
  9. 9

    Delayed diagnosis of 3β-HSD7 deficiency in adolescence: Two case reports and review of the literature.

    Pendleton S, Mostafavi M, Mathew J, et al.

    JPGN reports 2026; (7(2)):236-241 doi:10.1002/jpr3.70159.

    PMID: 42110141
  10. 10

    Protocols of Investigation of Neonatal Cholestasis-A Critical Appraisal.

    Quelhas P, Jacinto J, Cerski C, et al.

    Healthcare (Basel, Switzerland) 2022; (10(10)) doi:10.3390/healthcare10102012.

    PMID: 36292464
  11. 11

    Psychosocial impacts of caring for a child with a genetic disorder in Accra, Ghana.

    Opoku P, Osei-Tutu A, Oti-Boadi M

    Journal of community genetics 2023; (14(6)):565-574 doi:10.1007/s12687-023-00662-y.

    PMID: 37581869
  12. 12

    The Association between Healthcare Satisfaction and Social Support and Stress, Depression, and Life Satisfaction in Female Caregivers: The Moderating Role of Dependence of a Sick Child.

    Pavić J, Krznar M, Čukljek S, et al.

    International journal of environmental research and public health 2024; (21(9)) doi:10.3390/ijerph21091245.

    PMID: 39338128
  13. 13

    Genetic spectrum and clinical characteristics of 3β-hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7) deficiency in China.

    Zhao J, Setchell KDR, Gong Y, et al.

    Orphanet journal of rare diseases 2021; (16(1)):417 doi:10.1186/s13023-021-02041-7.

    PMID: 34627351
  14. 14

    Alone in a Crowd? Parents of Children with Rare Diseases' Experiences of Navigating the Healthcare System.

    Baumbusch J, Mayer S, Sloan-Yip I

    Journal of genetic counseling 2018; doi:10.1007/s10897-018-0294-9.

    PMID: 30128673

This page explains CBAS1 and HSD3B7 deficiency for parents and guardians for informational purposes only and does not constitute medical advice. Your child’s liver specialist and genetic counselor can interpret their results and treatment needs.